INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO
Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has officially transitioned its CORDStrom™ platform patent application into the U.S. national phase before the